The Q32 Bio Inc. (QTTB) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K that highlight material events. Q32 Bio’s filings reflect its status as a Nasdaq-listed clinical stage biotechnology company focused on alopecia areata and other autoimmune and inflammatory diseases.
Recent Form 8-K filings referenced by Q32 Bio include reports furnished under Item 2.02 for quarterly financial results and corporate updates, and under Item 8.01 for other events such as clinical trial milestones. For example, the company has filed 8-Ks in connection with press releases announcing financial results for specific quarters, as well as an 8-K describing the completion of enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial of bempikibart for alopecia areata. Another 8-K details leadership changes under Item 5.02, including the resignation of a Chief Medical Officer and the appointment of an interim Chief Medical Officer.
Q32 Bio’s 8-K filings also confirm that its common stock, with a par value of $0.0001 per share, is registered pursuant to Section 12(b) of the Exchange Act and trades on Nasdaq under the symbol QTTB. The filings typically attach press releases as exhibits, which are incorporated by reference where specified, and clarify whether the information is being furnished rather than filed for purposes of Section 18 of the Exchange Act.
On Stock Titan, these SEC documents are updated as they become available from EDGAR and are paired with AI-powered summaries that explain the key points in accessible language. Users can quickly see which filings relate to financial results, clinical trial updates, leadership changes, or other corporate events, and can review the underlying forms and exhibits for more detail.
Q32 Bio Inc. is asking stockholders to vote at its all-virtual 2026 annual meeting on June 12, 2026. Investors will elect three Class II directors to terms running to the 2029 meeting, ratify Ernst & Young LLP as auditor for 2026, and cast a non-binding advisory vote on executive pay. The record date is April 15, 2026, when 15,629,463 common shares were outstanding. The board unanimously recommends voting FOR all three proposals and offers multiple ways to vote by internet, phone, mail, QR code, or during the virtual meeting.
Q32 Bio Inc. entered a new phase of its at-the-market stock offering program by filing an additional prospectus supplement that covers up to $75,000,000 of common stock to be sold through Cantor Fitzgerald & Co. under an existing Controlled Equity Sales Agreement.
The company previously sold $14,200,000 of common stock under an earlier prospectus supplement, which is now fully used and terminated. Future sales of the additional shares, if any, will be made under Q32 Bio’s effective Form S-3 shelf registration statement.
Q32 Bio Inc. is registering $75,000,000 of common stock for sale from time to time through or to Cantor Fitzgerald & Co. under a Controlled Equity Sales Agreement as an at-the-market offering. The sales agent may act as agent or principal and is entitled to a 3.0% commission on gross proceeds. The company previously sold $14,200,000 under the prior prospectus supplement and has terminated that prior supplement. The number of shares outstanding was 12,858,047 as of December 31, 2025, and the prospectus assumes an illustrative price of $6.48 per share.
Net proceeds will be received by the issuer and are planned for working capital and clinical development, including support of bempikibart (ADX-914) development in alopecia areata. Sales may occur at varying prices and times; Cantor has no obligation to sell any set amount and the offering may be suspended or terminated per the sales agreement.
Q32 Bio Inc. entered into a Controlled Equity Sales Agreement with Cantor Fitzgerald & Co. to establish an at-the-market stock offering program. Under this agreement, Q32 Bio may sell shares of its common stock from time to time, with an aggregate offering price of up to $14,200,000.
The shares will be issued under an effective Form S-3 shelf registration and a related prospectus supplement. Q32 Bio will control key sale parameters and is not obligated to sell any shares. Cantor Fitzgerald will act as sales agent on a commercially reasonable efforts basis and receive a 3.0% cash commission on gross proceeds.
Q32 Bio Inc. is offering up to $14,200,000 of Common Stock through an at-the-market sales agreement with Cantor Fitzgerald & Co.
The company may sell shares from time to time under the sales agreement, with Cantor acting as sales agent or principal and receiving a 3.0% commission on gross proceeds. Sales are intended to be conducted as an at the market offering and are subject to the terms of the sales agreement. The prospectus supplement cites a March 26, 2026 last reported sale price of $7.14 per share and discloses a public float calculation used to limit offerings under Form S-3 General Instruction I.B.6.
Violette Shelia M. reported acquisition or exercise transactions in this Form 4 filing.
Q32 Bio Inc. Chief Scientific Officer Shelia M. Violette received a grant of 37,500 restricted stock units on February 24, 2026, at no cash cost per unit. The RSUs vest in four equal installments: 25% after 6 months from the grant date and 25% after 12, 24, and 36 months, with each RSU representing one share of common stock.
After this award, she directly holds 93,069 common shares. She is also a manager of Violette Holdings LLC, which holds 36,277 common shares; she disclaims beneficial ownership of those indirect shares except to the extent of her pecuniary interest.
Q32 Bio Inc. reported that its CFO and President, Lee Kalowski, received an equity award of 53,250 shares of common stock in the form of restricted stock units. This is a compensation-related grant at a price of $0.00 per share, not an open‑market purchase.
The RSUs vest in four equal 25% installments starting six months after the February 24, 2026 grant date, then at 12, 24, and 36 months from that date. Each RSU converts into one share of common stock upon vesting. After this grant, Kalowski holds 89,193 shares directly.
Morrison Jodie Pope reported acquisition or exercise transactions in this Form 4 filing.
Q32 Bio Inc. reported that CEO and director Jodie Pope Morrison received a grant of 132,000 shares of Common Stock on February 24, 2026 at a price of $0.0000 per share. Following this award, her directly held Common Stock position is 221,104 shares.
The award is structured as restricted stock units (RSUs). The RSUs vest in four equal 25% installments: 6, 12, 24, and 36 months from the February 24, 2026 grant date. Each RSU represents a contingent right to receive one share of Q32 Bio common stock as it vests.
OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC filed Amendment No. 1 to their Schedule 13D on Q32 Bio Inc., reporting beneficial ownership of 2,252,987 shares of common stock, or 15.4% of the outstanding shares.
The filing explains that their ownership percentage decreased by more than 1% because Q32 Bio’s total shares outstanding increased, not because OrbiMed changed its share count. The 15.4% figure is based on 14,629,463 shares outstanding as set forth in Q32 Bio’s Form 10‑K filed on March 1, 2026.
The shares are held by OrbiMed Private Investments VII, LP, with OrbiMed GP as its general partner and OrbiMed Advisors as managing member, giving them shared voting and dispositive power. OrbiMed indicates it may buy or sell Q32 Bio shares in the future depending on company performance, market conditions and other factors, but states it has no current plans for corporate control actions such as mergers, board changes or major asset sales.
Q32 Bio Inc. is a clinical-stage biotechnology company focused on restoring healthy immune balance, led by its antibody bempikibart for alopecia areata and other autoimmune diseases. Bempikibart blocks IL‑7 and TSLP signaling and has completed two Phase 2a trials in alopecia areata and atopic dermatitis with a favorable safety profile and biomarker changes consistent with its mechanism. The ongoing SIGNAL‑AA Part B Phase 2a trial in severe and very severe alopecia areata has enrolled 33 patients for 36 weeks of treatment, with 36‑week topline data expected in mid‑2026, and the FDA has granted Fast Track designation for alopecia areata. Q32 sold its Phase 2 complement asset ADX‑097 to Akebia Therapeutics, receiving a $7.0 million upfront payment, a $3.0 million payment at six months, a $2.0 million near‑term milestone and eligibility for up to $580 million in additional milestones plus tiered royalties. The company retains its tissue‑targeted complement platform, including ADX‑096, and holds or licenses intellectual property expected to protect bempikibart compositions to 2040 and methods of use to 2044.